Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasPsychopharmacology — metabolic syndrome and psychotropic monitoring

Psych Vivas · Psychopharmacology — metabolic syndrome and psychotropic monitoring

Metabolic syndrome and psychotropic monitoring — consultant viva

Fellowship viva on metabolic criteria, agent hierarchy, monitoring schedule, mechanisms, metformin/switch evidence and special populations.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner cards: ATP III/IDF components; clozapine/olanzapine vs aripiprazole ranking; ADA/APA 4/8/12-week weight; Correll 2009 youth; CATIE metabolic trade-off; H1/5-HT2C; Wu and Jarskog metformin; switch to aripiprazole; keep clozapine in TRS; who owns the bloods.

Station structure

Time: 8–10 minutes. Depth: consultant teaching registrar. Expect named criteria, hierarchy, schedule numbers, and named trials — not vague “monitor physical health”.[1][7]

Core questions and model points

  1. Define MetS? Cluster of central obesity/waist, high TG, low HDL, raised BP, raised fasting glucose; NCEP three-of-five vs IDF waist-required frameworks.[10]

  2. Why care in psychiatry? High MetS prevalence in SMI; CVD drives premature mortality; drugs amplify risk; monitoring gaps are system failures.[7][8]

  3. Rank agents? Highest: clozapine, olanzapine. High–moderate: quetiapine. Intermediate: risperidone/paliperidone. Lower weight: aripiprazole, ziprasidone, lurasidone (relative).[2][7]

  4. Mechanisms? H1/5-HT2C appetite; insulin resistance; atherogenic lipids; lifestyle multipliers.[7]

  5. ADA/APA schedule? Baseline package; weight 4/8/12 weeks then quarterly; glucose/lipids/BP structured rechecks; act earlier if trajectory bad.[1]

  6. Youth? Correll 2009 — large early cardiometabolic shifts with first SGA exposure; denser early monitoring.[4]

  7. CATIE pearl? Effectiveness vs metabolic trade-offs; olanzapine not “free” efficacy.[3]

  8. Interventions? Lifestyle from day 0; switch when possible (e.g. to aripiprazole); metformin evidence (Wu; Jarskog); treat BP/lipids/diabetes to target.[5][6][9]

  9. Metformin teaching dose? Start ~500 mg oral with food, titrate toward 1–2 g/day if eGFR allows; contraindications; adjunct not replacement for choice/monitoring.[5][6]

  10. Clozapine exception? Unique TRS efficacy → intensive metabolic management rather than casual cessation.[7][6]

  11. Ownership? Psychiatrist owns the plan and escalation even when GP draws bloods; written shared-care checklist.[1][7]

Distinctions that score

Score by separating ranking vs absolute need to monitor, using early weight trajectory as an action trigger, naming Wu/Jarskog for metformin, and refusing both metabolic nihilism (“ignore the labs”) and psychiatric nihilism (“stop all antipsychotics”).[1][5][6][7]

References

  1. [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
  2. [2]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730
  3. [3]Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med, 2005.PMID 16172203
  4. [4]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
  5. [5]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
  6. [6]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
  7. [7]De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat Rev Endocrinol, 2011.PMID 22009159
  8. [8]Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis Schizophr Bull, 2013.PMID 22207632
  9. [9]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
  10. [10]Alberti KG, Zimmet P, Shaw J Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med, 2006.PMID 16681555